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Summary
Background Lack of evidence-based outcomes data leads to uncertainty in developing treatment regimens in children 
who are newly diagnosed with ulcerative colitis. We hypothesised that pretreatment clinical, transcriptomic, and 
microbial factors predict disease course.
Methods In this inception cohort study, we recruited paediatric patients aged 4–17 years with newly diagnosed ulcerative 
colitis from 29 centres in the USA and Canada. Patients initially received standardised mesalazine or corticosteroids, 
with pre-established criteria for escalation to immunomodulators (ie, thiopurines) or anti-tumor necrosis factor-α 
(TNFα) therapy. We used RNA sequencing to define rectal gene expression before treatment, and 16S sequencing to 
characterise rectal and faecal microbiota. The primary outcome was week 52 corticosteroid-free remission with no 
therapy beyond mesalazine. We assessed factors associated with the primary outcome using logistic regression models 
of the per-protocol population. This study is registered with ClinicalTrials.gov, number NCT01536535.
Findings Between July 10, 2012, and April 21, 2015, of 467 patients recruited, 428 started medical therapy, of whom 
400 (93%) were evaluable at 52 weeks and 386 (90%) completed the study period with no protocol violations. 
150 (38%) of 400 participants achieved week 52 corticosteroid-free remission, of whom 147 (98%) were taking 
mesalazine and three (2%) were taking no medication. 74 (19%) of 400 were escalated to immunomodulators alone, 
123 (31%) anti-TNFα therapy, and 25 (6%) colectomy. Low baseline clinical severity, high baseline haemoglobin, 
and week 4 clinical remission were associated with achieving week 52 corticosteroid-free remission (n=386, logistic 
model area under the curve [AUC] 0·70, 95% CI 0·65–0·75; specificity 77%, 95% CI 71–82). Baseline severity and 
remission by week 4 were validated in an independent cohort of 274 paediatric patients with newly 
diagnosed ulcerative colitis. After adjusting for clinical predictors, an antimicrobial peptide gene signature (odds ratio 
[OR] 0·57, 95% CI 0·39–0·81; p=0·002) and abundance of Ruminococcaceae (OR 1·43, 1·02–2·00; p=0·04), and 
Sutterella (OR 0·81, 0·65–1·00; p=0·05) were independently associated with week 52 corticosteroid-free remission.
Interpretation Our findings support the utility of initial clinical activity and treatment response by 4 weeks to 
predict week 52 corticosteroid-free remission with mesalazine alone in children who are newly diagnosed with 
ulcerative colitis. The development of personalised clinical and biological signatures holds the promise of informing 
ulcerative colitis therapeutic decisions.
Funding US National Institutes of Health.
Introduction
Children diagnosed with ulcerative colitis typically have a 
moderate-to-severe disease course with high corti costeroid 
dependency and corticosteroid refractory disease driving 
frequent escalation to immunomodulators and anti-tumor 
necrosis factor-α (TNFα) therapy.1,2 Up to 26% of children 
diagnosed with ulcerative colitis have a colectomy within 
5 years.1,3 We hypothesised that in adults and children 
the course of ulcerative colitis depends on initial disease 
phenotype, therapy offered, and intrinsic patient biology. 
Initial disease severity, lack of response to early therapy, 
hypoalbuminaemia, anaemia, low serum concentration of 
25-hydroxyvitamin D (25[OH]D), colonic histology, and
specific genetic polymorphisms have been associated with 
worse clinical outcomes;2,4–6 although these data largely
come from studies without standardised treatment and
many have focused on acutely ill patients being treated in
hospital. In a paediatric observational registry with no
standardisation of initial therapy,7 less than 40% of
children who were newly diagnosed with ulcerative colitis
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were in corticosteroid-free remission without the need 
for immunomodulators or anti-TNFα therapy 1 year after 
diagnosis.
The predicting response to standardised paediatric 
colitis therapy (PROTECT) study was undertaken to 
provide prospective evidence-based data on the disease 
course of children who are newly diagnosed with 
ulcerative colitis and treated with standardised protocols, 
and identify clinical features and biological pathways that 
would improve understanding of the pronounced 
variability in treatment response without the confounding 
of un controlled treatment and retrospective analyses. In 
PROTECT, we characterised rectal gene expression and 
the intestinal microbiome before treatment and in 
association with clinical outcomes to develop predictive 
models of disease course beyond clinical characteristics.
Methods
Study design and participants
In this prospective inception cohort study, we recruited 
children aged 4–17 years who were undergoing assess ment 
for ulcerative colitis from 29 centres (mostly hospitals) 
in the USA and Canada. Each child underwent an ileo-
colonoscopy and oesophagogastroduodenoscopy with 
biopsy, and a diagnosis of ulcerative colitis was made by 
use of established criteria.8 Patients were eligible if they had 
disease beyond the rectum, a baseline Pediatric Ulcerative 
Colitis Activity Index (PUCAI) score of 10 or more, no 
previous therapy for colitis, and stool culture negative for 
enteric bacterial pathogens and Clostridium difficile toxin. 
Exclusion criteria included evidence of Crohn’s disease, 
use of oral corticosteroid within 4 weeks before diagnosis 
(full inclusion and exclusion criteria are in the appendix).
Each site’s institutional review board approved the 
protocol and safety monitoring plan. Informed consent 
or assent was obtained for each participant.
Procedures
Initial therapy was based on disease severity and in-
cluded mesalazine or oral or intravenous corticosteroids. 
Standardised treatment guidelines with indications for 
adding mesalazine, stopping steroids, or escalation to 
anti-TNFα therapy or immunomodulators (ie, thiopurines) 
or colectomy are in the appendix.
Clinical and routine laboratory data were collected at 
diagnosis and weeks 4, 12, and 52, as previously reported.9 
We determined disease activity using PUCAI10 and Mayo 
scores.11 Rectal biopsy samples were obtained from the 
most inflamed part of the rectosigmoid and histology 
was assessed centrally by a pathologist (MHC) and a his-
tological severity score defined (appendix).12 Faecal 
calprotectin concentration was determined centrally, 
as previously described.13 High density DNA genotyping 
was done using the Affymetrix UK Biobank Axiom 
Research in context
Evidence before this study
The lack of strong evidence-based outcomes data leads to 
uncertainty when developing treatment regimens for children 
who are newly diagnosed with ulcerative colitis, whose disease 
course might be unpredictable on the basis of initial clinical 
features alone. Robust controlled clinical trial data are not 
available in children, and current practice is largely based on 
extrapolation from adult data. We searched PubMed for studies 
published in English before Dec 31, 2017, using the MeSH terms 
“ulcerative colitis”, “corticosteroids”, “5-aminosalicylates”, 
“treatment”, and “outcomes”. We identified no systematic 
prospective studies of initial standardised therapy in children 
who were treatment naive or large scale microbiome and 
transcriptomic studies of stool samples and rectal tissue obtained 
at diagnosis to aid in predicting disease outcome at 1 year. 
Although studies did identify specific clinical factors associated 
with treatment outcomes, these factors were limited by small 
sample sizes, uncontrolled therapies, and lack of replication. 
Added value of this study
Our multicentre study of 428 treatment naive children with 
ulcerative colitis establishes for the first time, to our knowledge, 
prospective, controlled outcome data at 1 year after standardised 
initial therapy with mesalazine or corticosteroid. We developed a 
clinical model for week 52 corticosteroid-free remission with 
mesalazine alone that includes baseline clinical and laboratory 
factors and week 4 response to standardised therapy, and then 
validated the model in an independent cohort. A similar model 
with high specificity was developed to predict escalation to anti-
tumour necrosis factor-α therapy in our primary cohort. We found 
that rectal gene expression and gut microbial factors not only 
improved our ability to predict clinical outcomes beyond initial 
disease severity and laboratory characteristics, but also provided 
crucial insight into the biological reasons for widely disparate 
patient courses. These data highlighted more robust host innate 
immune responses, and loss of microbial Clostridiales taxa, 
in worse outcomes after controlling for clinical severity. 
Implications of all the available evidence
Our study has replicated several previous reports of clinical factors 
linked to outcomes in ulcerative colitis, and for the first time, 
to our knowledge, developed and validated a clinical model for 
week 52 corticosteroid-free remission with mesalazine alone in 
two large paediatric inception cohorts. These results will therefore 
have an immediate effect on clinical practice by providing specific 
parameters for initial disease activity, laboratory test results, 
and histological features, as well as early response to standardised 
therapy to guide therapeutic decisions. The transcriptomic and 
microbiome data reveal a possible mechanistic basis for success or 
failure of response to standardised therapy and the need for 
treatment escalation. Our data suggest that novel personalised 
interventions that account for these host–microbe interactions 
might be beneficial in both guiding more rational use of current 
therapies and developing novel microbial interventions. 
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Array (Thermo-Fisher, Waltham, MA, USA),14 and MEMS 
TrackCap technology (Aardex Group, Seriang, Belgium) 
was used to monitor mesalamine adherence. RNA 
sequencing and the global pattern of gene ex pression of 
rectal biopsy samples before treatment were determined 
using RNAseq on the Illumina platform (Illumina, 
San Diego, CA, USA)15 and validated on the Lexogen 
platform (Lexogen, Vienna, Austria).16 Rectal and faecal 
microbiome was profiled using 16S rRNA amplicon 
sequencing of the V4 region.17 Full details of procedures 
are in the appendix.
Outcomes
The primary outcome was week 52 corticosteroid-free 
remission, defined as clinical remission (PUCAI score of 
<10) with no corticosteroid use for 4 weeks or longer 
immedi ately before week 52, no medical therapy beyond 
mesalazine, and no colectomy. The secondary outcome 
was escalation to anti-TNFα therapy at any time in 
the 52 weeks. Additional outcomes were escalation to 
immuno modulators (ie, thiopurine, methotrexate) only, 
and colectomy. Week 4 remission was defined as a PUCAI 
score of less than 10 irrespective of corticosteroid status 
but without immunomodulator or anti-TNFα use, or 
colectomy. Week 12 corticosteroid-free remission was 
defined as a PUCAI score of less than 10 at week 12 and 
corticosteroid-free for the previous 14 days with no previous 
treatment escalation or colectomy.
We further defined baseline disease severity using a 
combination of initial PUCAI score and initial therapy 
as mild (mesalazine, or PUCAI score of <45 with oral 
corti costeroid) or moderate to severe (oral corticosteroid 
use with PUCAI score of ≥45, or intravenous cortico-
steroids regardless of PUCAI score) on the basis of 
previous observations of this cohort,9 in which a PUCAI 
score of less than 45 was identified as the only predictor 
(odds ratio [OR] 4·38, 95% CI 1·81–10·6; p=0·0011), other 
than remission at week 4, of corticosteroid-free remission 
at week 12 in the subgroup starting on oral steroids.
Statistical analysis
Statistical methods were prespecified in an analysis plan 
and are fully described in the appendix. We planned a 
sample size of 430 patients to ensure 90% power to 
identify an OR of 2·50 in predictive modelling—a 
value we expected to be clinically meaningful. Clinical 
predictors were modelled using the per-protocol 
population—ie, excluding participants with protocol 
violations and early study discontinuations with unknown 
outcomes. For analysis of biological predictors, we 
restricted sample selection for the primary Illumina 
platform gene-expression discovery analysis (ie, RNA 
sequencing) to patients who were treated per-protocol, 
with mesalazine as the initial therapy for patients with 
mild disease, and corticosteroids as the initial therapy for 
patients with moderate-to-severe disease. We aimed to 
study equal numbers who did or did not achieve week 4 
remission because our preliminary data showed that 
week 4 remission was highly associated with week 52 
corticosteroid-free remission. Because of low enrolment 
of patients with mild disease, and patients with moderate-
to-severe disease younger than 12 years, we selected all 
available patients meeting the selection criteria for these 
groups. Among the moderate-to-severe group aged 
12 years and older, we prioritised patients with complete 
stool sample collection. Statistical tests were done at a 
two-sided α level of 0·05 with no adjustment for multiple 
com parisons, unless otherwise specified. 
We used an independent prospective inception cohort 
of children newly diagnosed with ulcerative colitis7 to 
test the clinical model for week 52 corticosteroid-free 
remission. These patients, diagnosed between 2002 and 
2010 at 31 centres in the USA and Canada, pros pectively 
had clinical data obtained at diagnosis, 1 month after 
diagnosis, and quarterly. Treatment was by provider 
dictate, not protocol.
We developed prediction models for PROTECT clinical 
data using multiple imputation multivariable logistic 
regression with least absolute shrinkage and selection 
operator (LASSO)18 variable selection to account for 
missing data and obtain a parsimonious model. We 
defined genes from rectal biopsy samples that were 
differentially expressed at baseline for patients who were 
diagnosed with moderate-to-severe disease who achieved 
and who did not achieve week 52 corticosteroid-free 
remission with a fold change of 1·5 or higher and a false 
discovery rate of less than 0·05. We used ToppGene, 
ToppCluster, and Cytoscape in gene set enrichment 
analyses to identify enriched biological pathways within 
these genes, and we built principal components (PCs) 
from the gene signa tures. We identified differentially 
abundant microbial organisms associated with week 52 
corticosteroid-free remission at a false discovery rate 
of 0·2 and with escalation to anti-TNFα therapy at a false 
discovery rate of 0·05 by multivariable analyses 
accounting for key clinical and demographic covariates. 
We did a principal coordinates analysis (PcoA) to 
summarise variation in gene expression between patients, 
and PC values were extracted for downstream analyses. 
We tested improvement of clinical prediction models on 
the addition of each identified gene expression PC or 
microbial taxon individually, with variables retained at a 
p value of less than 0·05. We then tested the PCs and 
microbial taxa identified for simultaneous inclusion in 
the clinical models, in which improvement over the 
clinical model was assessed via comparison of the area 
under the receiver operator characteristic (ROC) curve 
(AUC). We assessed the association between predictors 
using Spearman correlation. 
For the PROTECT main RNA sequence discovery 
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See Online for appendixUSA). For validation of the gene signatures, we used RNA 
sequence data from an independent cohort, the RISK 
cohort,20 including 43 patients with ulcerative colitis, 
93 with Crohn’s disease with rectal inflammation, a nd 
55 non-IBD controls. The controls we used for the 
PROTECT and RISK datasets were suspected to have IBD, 
but with normal radiographic, endoscopic, and histological 
findings. 
We did all statistical testing of predictive models of 
outcomes using SAS version 9.4. This study is registered 
with ClinicalTrials.gov (NCT01536535).
Role of the funding source
The study was performed under a cooperative agreement 
with the funder, who was involved in the study design, 
data collection, data analysis, data interpretation, and 
writing of the report. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between July 10, 2012, and April 21, 2015, 467 patients 
were enrolled, of whom 36 (8%) were disqualified because 
of change of diagnosis to Crohn’s disease or other protocol 
violations, and three (<1%) patients or their families 
declined medical therapy. 428 participants started medical 
therapy, of whom 386 (90%) were strictly per protocol 
(figure 1 ). B aseline c haracteristics f or t he w hole c ohort 
and by disease severity are in table 1. The mean age was 
12·7 years (SD 3·3), 212 (50%) of 428 participants were 
female, and 69 (16%) of 420 were non-white (eg, Asian, 
African American, American Indian, Alaskan Native, 
Pacific I slander). 1 78 ( 42%) p articipants p resented w ith 
mild disease (mean PUCAI score 31·9 [SD 12·1]; mean 
total Mayo score 5·7 [SD 1·8]); of whom 136 (76%) were 
initially given mesalazine and 42 (24%) oral corticosteroids. 
250 (58%) participants presented with moderate-to-severe 
disease (mean PUCAI score 62·9 [SD 13·2]; mean total 
Mayo score 9·3 [SD 1·7]), of whom 102 (41%) were initially 
given oral corticosteroids and 148 (59%) were given intra-
venous corticosteroids. 286 (67%) participants received 
the initial treatment recommended by the standardised 
treatment algorithm (appendix). By week 52, 387 (90%) 
participants received mesalazine at some point, with 
293 providing adherence data based on MEMS-Cap use 
between week 4 and week 52 or escalation to additional 
therapy. On average, 84% (SD 21) of prescribed mesalazine 
doses were taken (82% [SD 21] by partic ipants with mild 
disease vs 85% [SD 22] with moderate-to-severe disease; 
p=0·12). 28 (6%) of 428 participants discontinued the 
study be fore week 52 without previous colectomy or 
escalation to immuno modulators or anti-TNFα therapy, 
leaving 400 (93%) par ticipants who were evaluable 
at week 52. An additional 14 patients were excluded from 
predictive modelling because of protocol violations; hence, 
the per-protocol population comprised 386 participants. 
Complete biological data were available for a subset of 
177 par ticipants, and 206 had data from RNA sequencing 
and 343 had microbiome data.
By week 52, 150 (38%) of 400 participants achieved 
corticosteroid-free remission (80 [49%] of 163 with mild 
disease and 70 [30%] of 237 with moderate-to-severe 
disease; appendix). 147 (98%) of 150 were taking mesalazine 
and three (2%) were taking no med ication. 98 (65%) of 
150 participants who achieved remission by week 52 
supplied stool samples at that time, of whom 56 (57%) 
had faecal calprotectin concentrations below 250 μg/g. 
Of 231 patients who supplied stool samples for analysis 
at week 52, corticosteroid-free remission with faecal 
calprotectin concentration below 250 μg/g was achieved 
by 56 (24%).
Of 400 participants who were evaluable at 52 weeks, 
74 (19%) were given immunomodulators as the only 
additional medical therapy (18 [11%] of 163 with mild 
disease and 56 [24%] of 237 with moderate-to-severe 
disease) and 123 (31%) escalated to anti-TNFα, including 
Figure 1: Trial profile
*Three participants were on both oral steroids and mesalazine, and one participant 
received intravenous steroids for 1 day without being admitted to hospital. 
†The evaluable population at week 52 include 17 participants who discontinued 
after additional therapy (immunomodulator, calcineurin inhibitor, or anti-tumor 
necrosis factor-α) or colectomy. ‡Include nine participants on oral 
corticosteroids and mesalazine.
467 patients enrolled
431 patients with ulcerative colitis enrolled
428 included at baseline
136 initiated on mesalazine only
144 initiated on oral corticosteroids*
148 initiated on intravenous corticosteroids
400 evaluable at week 52† 
5 received no treatment
187 received mesalazine only
10 received oral corticosteroids‡
1 received intravenous corticosteroids 
172 received additional therapy
25 underwent colectomy
36 baseline violations
28 did not have ulcerative colitis
8 other reason
3 treatment violations (not treated)
28 discontinued without additional therapy or 
colectomy
14 per-protocol exclusions
2 additional therapy for liver disease
4 investigator choice
8 treatment interruptions of >28 days
one patient who escalated to calcineurin inhibitor and 
one who received an emergent colectomy before anti-
TNFα therapy (28 (17%) with mild disease and 95 [40%] 
with moderate-to-severe disease). 25 (6%) of 400 parti-
cipants had a colectomy (two (1%) with mild disease and 
23 (10%) with moderate-to-severe disease). The time-
course of treatments is shown in the appendix.
Figure 2 shows time until corticosteroid-free remission 
and escalation to anti-TNFα by initial disease presentation. 
Participants who presented with mild disease continued 
to achieve corticosteroid-free remission from week 4 
until week 52, whereas those who presented with 
moderate-to-severe disease and who achieved corti -
costeroid-free remission had largely done so by week 16. 
Of the 95 participants with moderate-to-severe disease 
who escalated to anti-TNFα therapy, 41 (43%) had done so 
by week 4 (figure 2B). After week 4, participants with mild 
disease and with moderate-to-severe disease escalated to 
anti-TNFα therapy at similar incidences. At week 52, 
50 (48%) of 105 participants who escalated to anti-TNFα 
therapy and had 1 year of follow-up were in clinical 
remission (table 2). Time to corticosteroid-free remis-
sion, escalation to immuno modulators, anti-TNFα thera-
py, and colectomy as a function of remission status 
at week 4 are shown in the appendix. Of 211 participants 
who did not achieve remission by week 4, 21 (10%) had 
by week 16; however, few ultimately reached corticosteroid-
free remission by week 52 (50 [24%] of 211). Conversely, 
38 (18%) of 211 who achieved week 4 remission escalated 
to anti-TNFα primarily between weeks 16 and 52.
Baseline characteristics, remission by week 4, corti-
costeroid-free remission by week 12, and week 52 PUCAI 
scores by outcome at week 52 are shown in table 2 
(additional baseline characteristics, and for the moderate-
to-severe subgroup, are in the appendix). Incidence of 
outcomes did not vary with age, sex, or race. As expected, 
patients who achieved corticosteroid-free remission by 
week 52 were more likely to have mild disease as 
determined by clinical and endoscopic analysis, higher 
haemoglobin and albumin concentrations, lower acute 
phase reactants (ie, C reactive protein and erythrocyte 
sedimenation rate), and higher incidences of remission 
by week 4 and week 12 than those who did not achieve 
corticosteroid-free remission by week 52. However, 
substantial variability was seen, with 41 (31%) of 
133 par ticipants with a baseline PUCAI score of 65 of 
higher achieving week 52 corticosteroid-free remission, 
and 13 (14%) of 90 par ticipants with a PUCAI score 
below 35 escalated to anti-TNFα therapy by week 52 
(table 2). We observed that the bioavailable fraction of 
25(OH)D was higher in those who achieved week 52 
corticosteroid-free remission than those who did not 
achieve 52 week corticosteroid-free remission (median 
1·5 ng/mL vs 1·2–1·3 ng/mL; p=0·0091; table 2). In 
participants with moderate-to-severe disease, serum 
25(OH)D concentration and bioavailable fraction were 









Age, years 12·7 (3·3) 12·6 (3·4) 12·7 (3·2) 0·58
Sex
Female 212 (50%) 88 (49%) 124 (50%) 0·97
Male 216 (50%) 90 (51%) 126 (50%) ··
Race n=420 n=176 n=244 ··
White 351 (84%) 150 (85%) 201 (82%) 0·44
Non-white 69 (16%) 26 (15%) 43 (18%) ··
Ethnicity n=424 n=175 n=249 ··
Hispanic or Latino 38 (9%) 21 (12%) 17 (7%) 0·066
Not Hispanic or Latino 386 (91%) 152 (88%) 232 (93%) ··
BMI Z score –0·2 (1·3) –0·1 (1·2) –0·4 (1·4) 0·019
Initial treatment*
Mesalazine 136 (32%) 136 (76%) 0 ··
Oral corticosteroids 144 (34%) 42 (24%) 102 (41%) ··
Intravenous corticosteroids 148 (35%) 0 148 (59%) ··
Being treated in hospital at baseline (%) 166 (39%) 9 (5%) 157 (63%) <0·0001
Clinical
Symptoms
Abdominal pain 354 (83%) 126 (71%) 228 (91%) <0·0001
Diarrhoea 393 (92%) 144 (81%) 249 (100%) <0·0001
Rectal bleeding 398 (93%) 153 (86%) 245 (98%) <0·0001
Disease extent
Proctosigmoiditis 29 (7%) 23 (13%) 6 (2%) <0·0001
Left-sided colitis 44 (10%) 34 (19%) 10 (4%) ··
Extensive disease or pancolitis† 355 (83%) 121 (68%) 234 (94%) ··
PUCAI total score (range 0–85 in 
increments of 5)†
50·0 (19·9) 31·9 (12·1) 62·9 (13·2) <0·0001
<45 156 (36%) 148 (83%) 8 (3%) <0·0001
Mayo total score (range 0–12) 7·8 (2·5) 5·7 (1·8) 9·3 (1·7) <0·0001
≥10 120 (28%) 3 (2%) 117 (47%) <0·0001
≥11 71 (17%) 0 (0%) 71 (28%) <0·0001
Mayo endoscopy sub-score (range 0–3) 2·2 (0·7) 1·9 (0·6) 2·4 (0·6) <0·0001
Partial Mayo score (range 0–9) 5·6 (2·1) 3·9 (1·5) 6·8 (1·4) <0·0001
Haemoglobin, g/dL n=402 n=163 n=239 ··
Mean 11·4 (2·2) 12·2 (1·9) 10·9 (2·2) <0·0001
<10 98 (24%) 15 (9%) 83 (35%) ··
Erythrocyte sedimentation rate, mm/h n=385 n=155 n=230 ··
Median 25 (12–42) 16 (9–28) 32 (17–49) <0·0001
C-reactive protein or high sensitivity 
C-reactive protein
n=315 n=121 n=194 ··
>ULN 144 (46%) 36 (30%) 108 (56%) <0·0001
>2 × ULN 97 (31%) 19 (16%) 78 (40%) <0·0001
Albumin, g/dL n=422 n=174 n=248 ··
Mean 3·7 (0·7) 3·9 (0·7) 3·5 (0·7) <0·0001
<3·5 138 (33%) 37 (21%) 101 (41%) ··








<20 42 (11%) 17 (10%) 25 (11%) 0·70
20–30 183 (46%) 80 (49%) 103 (45%) ··
≥30 168 (43%) 66 (40%) 102 (44%) ··
(Table 1 continues on next page)
(median 26·6 ng/mL serum and 1·1 ng/mL bioavailable 
fraction) than those not escalated to anti-TNFα therapy 
(median 28·7–30·6 ng/mL for serum, p=0·026; median 
for bioavailable 1·1–1·3 ng/mL, p=0·055; appendix). 
Patients who escalated to anti-TNFα were less likely to 
have increased concentrations of eosinophils on rectal 
histopathological assessment than those who did not 
escalate to anti-TNFα therapy (45 [42%] of 107 vs 60–68%, 
p=0·0016; table 2); this observation was particularly 
apparent in those with moderate-to-severe disease 
(31 [37%] of 83 vs 54–74%, p=0·0004; appendix). Mesalazine 
adherence was not associated with achieving week 52 
corticosteroid-free remission or escalation to anti-TNFα 
therapy (appendix). Week 4 remission and week 12 
corticosteroid-free remission were both strongly associated 
with outcomes at week 52, and had a modest correlation 
(Spearman correlation 0·40, 95% CI 0·31–0·48; p<0·0001) 
in the week 52 evaluable population (n=400).
We identified a panel of 33 genes that were differ-
entially expressed in the rectum for patients with 
moderate-to-severe disease who did (n=51) and did not 
(n=101) achieve week 52 corticosteroid-free remission 
(figure 3; appendix). We identified 18 gene sets that were 
in creased, which were associated with cellular transport 
and channels, and 15 gene sets that were decreased and 
associated with antimicrobial responses (more infor-
mation is in the appendix). From the 206 participants 
who had RNA sequencing data, unsupervised hierarchal 
clustering of the gene panel was defined in 199 patients 
with ulcerative colitis (block 1 [n=3], blocks ii-a [n=79] and 
ii-b [n=117], full gene panel is in the appendix; figure 3A). 
Participants who achieved week 52 corti costeroid-
free remission were more likely to be in block ii-b 
(52 [69%] of 75 participants who achieved corticosteroid-
free remission in block ii; p=0·03), whereas those who 
escalated to anti-TNFα were more likely to be in block ii-a 
(42 [66%] of 64 who escalated to anti-TNFα in block ii; 
p=1 × 10–⁶). Gene set enrichment analysis of the gene 
panel identified epithelial transporters and channels, and 
antimicrobial peptides including α-defensins (the 
transport and antimicrobial gene signature; figure 3A). 
The α-defensins reactome antimicrobial peptide pathway 
showed a stronger negative association with week 52 
corticosteroid-free remission outcome (table 3), whereas 
the overall 33 gene set signature was negatively associated 
with need for escalation to anti-TNFα therapy (table 4). 
A specific antimicrobial peptide pathway was induced 
in ulcerative colitis compared with 20 age-matched 
and sex-matched controls (appendix), but in relatively 
lower con centrations than in many of the patients 
who achieved week 52 corticosteroid-free remission 
(appendix). Consis tent with this number, a greater 
number of α-defensin 5 (DEFA5) positive cells was 
detected in rectal biopsy samples from patients with 
ulcerative colitis who did not achieve week 52 cortico-
steroid-free remission than in samples from those 
who did and controls (appendix). By comparison, the
epithelial transport gene signature was suppressed in 
patients with ulcerative colitis compared with controls, 
and suppression was greatest in patients who escalated 
Figure 2: Time until corticosteroid-free remission (A) or escalation to anti-TNFα therapy (B) by initial disease 
presentation
Data are from a Kaplan-Meier analysis for all 428 participants who started therapy, of whom 178 presented with 
mild disease and 250 with moderate-to-severe disease. Time until event was censored at last contact for 
28 patients who discontinued before the week 52 study visit without treatment escalation. Differences between 































































































































































(Continued from previous page)
Bioavailable 25-hydroxyvitamin D, 
ng/mL








≥1·6 147 (38%) 79 (48%) 68 (30%) 0·00021
Rectal biopsy eosinophilic 








Data are mean (SD), n (%), n/N (%), or median (IQR). p values comparing groups are from a χ² test for categorical 
variables, a Mantel-Haenszel χ² test for ordinal variables, and ANOVA for continuous variables. Additional 
characteristics are in the appendix. BMI=body-mass index. PUCAI=Pediatric Ulcerative Colitis Activity Index. 
ULN=upper limit of normal. hpf=high power field. *Some participants received a different initial treatment from the 
recommended plan at the discretion of the treating physician. †Includes patients with fulminant disease  who were 
limited to colonoscopy.
















Age, years 12·3 (3·4) 12·4 (3·8) 12·9 (2·9) 12·9 (3·0) 0·30
Sex 
Female 69 (46%) 30 (57%) 36 (49%) 62 (50%) 0·60
Male 81 (54%) 23 (43%) 38 (51%) 61 (50%) ··
Race n=148 n=53 n=70 n=121
White 126 (85%) 44 (83%) 59 (84%) 101 (83%) 0·98
Non-white 22 (15%) 9 (17%) 11 (16%) 20 (17%) ··
Clinical
Extent of disease
Proctosigmoiditis 15 (10%) 5 (9%) 3 (4%) 4 (3%) 0·0041
Left-sided colitis 18 (12%) 8 (15%) 6 (8%) 6 (5%) ··
Extensive disease or pancolitis‡ 117 (78%) 40 (75%) 65 (88%) 113 (92%) ··
PUCAI total score (range 0–85 by 
increments of 5)
45·6 (20·3) 39·2 (16·3) 51·6 (15·4) 60·2 (18·1) <0·0001
<45 70 (47%) 34 (64%) 16 (22%) 23 (19%) <0·0001
Proportion of week 52 outcomes by PUCAI total score category 
10–30 (mild) n=90 43/90 (48%) 23/90 (26%) 11/90 (12%) 13/90 (14%) <0·0001
35–60 (moderate) n=177 66/177 (37%) 25/177 (14%) 45/177 (25%) 41/177 (23%) ··
≥65 (severe) n=133 41/133 (31%) 5/133 (4%) 18/133 (14%) 69/133 (52%) ··
Mayo total score (range 0–12) 7·2 (2·5) 6·5 (2·0) 7·9 (2·0) 9·1 (2·3) <0·0001
≥10 30 (20%) 6 (11%) 15 (20%) 64 (52%) <0·0001
≥11 13 (9%) 1 (2%) 8 (11%) 47 (38%) <0·0001
Mayo endoscopy score (range 0–3) 2·1 (0·7) 1·9 (0·6) 2·2 (0·6) 2·5 (0·6) <0·0001
Haemoglobin, g/dL n=139 n=49 n=68 n=120 ··
Mean 11·9 (2·0) 12·0 (1·9) 10·9 (2·3) 10·8 (2·3) <0·0001
<10 22 (16%) 7 (14%) 22 (32%) 45 (38%) 0·0001
Erythrocyte sedimentation rate, mm/h n=135 n=44 n=64 n=115 ··
Median 19 (11–34) 17 (9–35) 28 (12–47) 30 (17-46) 0·0005
C-reactive protein or high sensitivity 
C-reactive protein
n=113 n=37 n=51 n=100
>ULN 42 (37%) 12 (32%) 24 (47%) 59 (59%) 0·0044
Albumin, g/dL n=147 n=53 n=71 n=123 ··
Mean 3·8 (0·7) 3·8 (0·8) 3·6 (0·6) 3·5 (0·7) 0·0001
<3·5 40 (27%) 15 (28%) 22 (31%) 55 (45%) 0·0155
Serum 25-hydroxyvitamin D, ng/mL n=136 n=50 n=68 n=113 ··
Median 29·5 (25·0–36·9) 28·8 (24·2–34·0) 28·7 (24·4–35·1) 27·1 (22·2–31·7) 0·055
<20 12 (9%) 5 (10%) 3 (4%) 19 (17%) 0·11
20–<30 61 (45%) 23 (46%) 34 (50%) 54 (48%) ··
≥30 63 (46%) 22 (44%) 31 (46%) 40 (35%) ··
Bioavailable 25-hydroxyvitamin D, 
ng/mL
n=136 n=51 n=66 n=112 ··
Median 1·5 (1·1–2·1) 1·3 (0·8–2·1) 1·2 (0·8–1·8) 1·2 (0·8–1·9) 0·0091
≥1·6 65 (48%) 20 (39%) 21 (32%) 36 (32%) 0·045
Rectal biopsy eosinophilic 
inflammation, count >32/hpf
75/126 (60%) 31/46 (67%) 43/63 (68%) 45/107 (42%) 0·0016
Week 4 remission§ 100/150 (67%) 27/53 (51%) 33/74 (45%) 38/123 (31%) <0·0001
Week 4 faecal calprotectin, μg/g n=108 n=39 n=48 n=78
Median 604·5 (144·8–1519·3) 677·6 (233·2–1597·7) 1014·3 (372·0–2314·2) 1576·8 (564·6–2975·5) 0·0008
Week 12 corticosteroid-free remission 79/150 (53%) 23/53 (43%) 15/74 (20%) 19/123 (15%) <0·0001
(Table 2 continues on next page)
to anti-TNFα therapy (appendix). A specific induction 
of the antimicrobial peptide gene signature and sup-
pression of the epithelial transport gene sig nature were 
confirmed in patients with ulcerative colitis compared 
with non-IBD controls and controls with Crohn’s disease 
involving the rectum in the independent RISK cohort 
(appendix).20
Microbes from the Clostridiales order have been 
implicated in maintenance of the function of the gut 
barrier and immune tolerance.21 Multivariable analyses 
identified taxa associated with week 52 corticosteroid-free 
remission (six at a false discovery rate of <0·2, with two at 
a false discovery rate of <0·05), and escalation to anti-
TNFα therapy (56 at a false discovery rate of <0·2, with 
26 at a false discovery rate of <0·05; appendix). Almost all 
of these taxa were increased in patients who achieved 
corticosteroid-free remission at week 52, and decreased 
in those who escalated to anti-TNFα therapy. These taxa 
included two operational taxonomic units from the 
Clostridiales order that were increased in patients who 
achieved week 52 corticosteroid-free remission, and 
20 Clostridiales operational taxonomic units that were 
decreased in patients who escalated to anti-TNFα therapy 
(false discovery rate of <0·05; appendix).
Mild clinical severity (PUCAI score of <45, regardless 
of initial treatment), week 4 remission, and baseline 
haemoglobin concentration of 10 g/dL or higher in those 
who did not achieve remission by week 4 were associated 
with achieving week 52 corticosteroid-free remission 
(table 3). The multivariable model of the per-protocol 
population (n=386) showed good discriminatory power 
and spec ificity, with an AUC of 0·70 (95% CI 0·65–0·75), 
a cross-validated AUC of 0·63 (0·57–0·69), and specificity 
of 77% (95% CI 71–82); table 3, appendix). A post-hoc 
model with week 12 corticosteroid-free remission instead 
of week 4 remission had a similar discriminatory power, 
with an AUC of 0·69 (95% CI 0·64–0·75) and specificity 
of 77% (95% CI 77–82; appendix).
Components of the clinical model were validated in 
an independent inception cohort of 307 paediatric 
ulcerative colitis patients enrolled in the prospective 
Pediatric Inflammatory Bowel Disease Collaborative 
Research Group Registry (appendix).7 Baseline clinical 
and demo graphic characteristics were quite similar 
between the IBD registry study and the PROTECT 
cohort. Disease activity of this independent cohort was 
classified using physician global assessment because 
enrolment occurred before the PUCAI was published.10 
Medical therapy was not standardised, and 86 (28%) 
of 307 patients achieved week 52 corticosteroid-free 
remission. Multi variable analysis in the 274 (89%) of 
307 participants with complete data confirmed that mild 
clinical disease activity at baseline (OR 1·7, 95% CI 
1·0–3·0; p=0·056) and week 4 inactive disease (2·8, 
1·7–4·8; p=0·0001) were associated with week 52 
corticosteroid-free remission, with similar discrimi-
natory power (AUC 0·65, 95% CI 0·59–0·71). Baseline 
haemo globin concentration did not achieve significance, 
but the direction of effect was consistent with the 
PROTECT clinical model (continuous haemoglobin OR 
1·08/1–unit increase; p=0·18; haemo globin ≥10 g/dL 
OR 1·55; p=0·19).
The association between the probability of achieving 
week 52 corticosteroid-free remission based upon the 
PROTECT clinical model and the antimicrobial peptide 
gene signature is shown the appendix. Patients with a 
lower antimicrobial peptide gene signature single gene-
expression PC (PC1) were more likely to achieve week 52 
corticosteroid-free remission than those with a higher 
concentrations of PC1. The addition of biological data on 
antimicrobial peptide gene signature and the relative 
abundance of Ruminococcaceae and Sutterella organisms 
to the clinical model improved the discriminantory power 
of the model, with an AUC of 0·75 (95% CI 0·68–0·83; 
p=0·014), a cross-validated AUC of 0·72 (95% CI 











Escalation to anti-TNFα 
therapy† (n=123)
p value
(Continued form previous page)
Week 52 PUCAI total score category n=149 n=51 n=69 n=105 ··
<10 (inactive) 149 (100%) 6 (12%) 40 (58%) 50 (48%) <0·0001
10–30 (mild) 0 39 (76%) 24 (35%) 32 (30%) ··
35–60 (moderate) 0 5 (10%) 3 (4%) 17 (16%) ··
≥65 (severe) 0 1 (2%) 2 (3%) 6 (6%) ··
Data are mean (SD), n (%), n/N (%), or median (IQR). Evaluable population excludes participants who discontinued the study without additional therapy or colectomy. p values 
comparing groups are from a χ² testfor categorical variables, a Mantel-Haenszel χ² test for ordinal variables, and ANOVA or Kruskal-Wallis test for continuous variables. Additional 
characteristics are in the appendix. PUCAI=Pediatric Ulcerative Colitis Activity Index. TNF=tumor necrosis factor. ULN=upper limit of normal. hpf=high power field. *106 patients 
started on immunomodulators, 32 later escalated to anti-TNFα. †Includes one patient starting a calcineurin inhibitor and one who received colectomy without escalation to 
anti-TNFα therapy. ‡Includes patients with fulminant disease with restricted colonoscopy. §PUCAI score of <10 at week 4 with no previous treatment escalation or colectomy.
Table 2: Baseline characteristics, week 4 remission, week 12 corticosteroid-free remission, and week 52 PUCAI score of the evaluable population by 
week 52 outcome
the subset with transcriptomic and microbial data 
(n=177; figure 3B). Patients with lower levels of 
antimicrobial peptide gene expression (OR 0·57, 95% CI 
0·39–0·81; p=0·002) and Sutterella organisms (0·81, 
0·65–1·00; p=0·05) and higher relative abundance of 
Ruminococcaceae (1·43, 1·02–2·00; p=0·04), were more 
likely to achieve week 52 corticosteroid-free remission 
than other patient groups.
Because 95 (40%) of 237 evaluable patients with 
moderate-to-severe disease escalated to anti-TNFα 
therapy by week 52 (appendix), we sought to define 
factors associated with this outcome. In the per-protocol 
population with moderate-to-severe disease (n=232), a 
total Mayo score of 11 or more and lack of remission by 
week 4 were associated with escalation to anti-TNFα 
therapy (table 4). Notably, baseline haemoglobin 
Figure 3: Gene set enrichment analysis (A) and receiver operator characteristic curves for week 52 corticosteroid-free remission (B) and escalation to 
anti-TNFα therapy or (C) colectomy as biological predictors of disease outcome
(A) 33 genes were differentially expressed in the rectum in participants with moderate-to-severe disease who achieved week 52 corticosteroid-free remission compared 
with those who did not. 18 increased genes (15 shown) were associated with cellular transport and channel, and 15 decreased gene sets (11 shown)  were associated 
with antimicrobial responses (more information is in the appendix). Genes are shown as hexagons, gene ontology as blue squares, drug-associations as orange squares,
and pathways, gene families, interactions, and co-expression are in different shades of green. The full list of results and p values are in the appendix. (B and C) ROC 
curves of outcomes from logistic regression models of patients with clinical data (red) and clinical and biological data (blue) from single imputation with the median 
AUC value out of the 100 multiple imputations. Panel B shows  data for the whole cohort and panel C for patients with moderate-to-severe disease. The cutpoint used 
to define sensitivity and specificity for each model is indicated by the filled circle. Panel B corresponds to data in table 3 and panel C to data in table 4. AUC=area under 
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con centrations of less than 10 g/dL, low serum 25(OH)D 
concentration, and low eosinophil count in rectal 
biopsy samples were also predictive of escalation to anti-
TNFα therapy in patients with moderate-to-severe 
disease (table 4). A model including these factors showed 
good discriminatory power, with an AUC of 0·78 (95% CI 
0·72–0·84), a cross-validated AUC of 0·75 (0·68–0·82), 
sensitivity of 58% (95% CI 47–68), and specificity of 85% 
(95% CI 78–92; table 4; appendix). A post-hoc model 
with week 12 corticosteroid-free remission instead of 
week 4 remission had a similar AUC of 0·78 (95% CI 
0·72–0·85), sensitivity of 59% (95% CI 48–69), and 
specificity o f 8 5% ( 95% C I 7 8–92). B ecause t otal Mayo 
score, serum 25(OH)D concentration, and rectal biopsy 
sample eosinophil count were not collected in the IBD 
Registry study,7 we were not able to use these data to 
validate this secondary model. The association between 
the probability of escalation to anti-TNFα therapy based 
on the clinical model and the transport and antimicrobial 
gene signature is shown in the appendix. Patients 
with a lower transport and antimicrobial gene signature 
PC1 were more likely to escalate to anti-TNFα therapy 
(appendix). The addition of biological data on transport 
and antimicrobial gene signature and the abundance of 
an Oscillospira species to the model improved the model 
fit with an AUC of 0·88 (95% CI 0·81–0·94; p=0·016), 
a cross-validated AUC of 0·84 (0·76–0·91), sensitivity 
of 66% (95% CI 52–80), and specificity of 83% (95% CI 
74–91) in the subset with transcriptomic and microbial 
data (n=118; figure 3C, table 4). Patients with low 
transport gene expression and Oscillospira concentrations 
and high antimicrobial gene expression had an increased 
likelihood of escalating to anti-TNFα therapy (table 4).
Discussion
In this study, despite utilisation of standardised initial 
therapy with mesalazine or corticosteroid, a minority of 
children with ulcerative colitis achieved the ideal clinical 
outcome of corticosteroid-free remission with mesalazine 
alone at 1 year after diagnosis. 19% of participants 
required additional medical therapy with immuno-
modulators such as thiopurines, 31%  were given anti-
TNFα therapy, and 6% required a colectomy within 1 year 
of diagnosis. These clinical outcomes are consistent 
with a previously reported1 incidence of 8% colectomy 
among children newly diagnosed with ulcerative colitis. 
All patients in clinical model* 
(n=386; 147 [38%] events)
Patients with biological data† (n=177; 69 [39%] events)
Estimate p value Clinical model Clinical and biological model
Estimate p value Estimate p value
Baseline predictors
PUCAI score <45 1·84 (1·18–2·89) 0·0077 NA NA ··
Haemoglobin ≥10 g/dL (without week 4 remission) 4·24 (1·46–12·31) 0·0080 6·79 (1·45–31·76) 0·015 5·72 (1·16–28·23) 0·032
Week 4 remission 9·50 (3·39–26·63) <0·0001 15·11 (3·39–67·44) 0·00037 14·92 (3·18–69·98) 0·00061
Antimicrobial peptide gene signature NA ·· NA ·· 0·57 (0·39–0·81) 0·0022
Ruminococcaceae (560535) OTU log relative abundance‡ NA ·· NA ·· 1·43 (1·02–2·00) 0·036
Sutterella (589923) OTU log relative abundance‡ NA ·· NA ·· 0·81 (0·65–1·00) 0·049
Model characteristics
AUC 0·70 (0·65–0·75) ·· 0·68 (0·61–0·75) ·· 0·75 (0·68–0·83) ··
Cross-validation AUC 0·63 (0·57–0·69) ·· 0·49 (0·40–0·58) ·· 0·72 (0·64–0·80) ··
R² 0·16 ·· 0·17 ·· 0·29 ··
Sensitivity 47% (39–55) ·· 70% (57–80) ·· 49% (38–61) ··
Specificity 77% (71–82) ·· 60% (50–69) ·· 78% (70–85) ··
Positive predictive value 56% (47–64) ·· 53% (42–63) ·· 58% (46–71) ··
Negative predictive value 70% (65–76) ·· 76% (65–84) ·· 71% (62–79) ··
Clinical plus biological model vs clinical model§
Likelihood ratio test NA NA NA NA ·· 0·00037
Comparison of AUC NA NA NA NA ·· 0·014
Hosmer-Lemeshow goodness-of-fit test, median multiple 
imputation p value (proportion of imputations with p >0·05)
·· 0·42 (100%) ·· 0·99 (100%) ·· 0·25 (100%)
Baseline predictors are odds ratio, unless otherwise stated, with 95% CIs in parentheses when appropriate. Missing covariate data imputed via multiple imputation. Clinical parameters selected by LASSO. Sensitivity, 
specificity, positive predictive value, and negative predictive value were based on a predicted probability of 0·50. The predicted probability of corticosteroid-free remission for a patient  with a PUCAI score of <45, 
haemoglobin ≥10 g/dL, and week 4 remission is 0·60 (for equation see appendix). Model fitting identified  an interaction between haemoglobin concentration and week 4 remission (p=0·042), which led to the final 
model with a predictor of haemoglobin ≥10 g/dL in the absence of  week 4 remission. PUCAI=Pediatric Ulcerative Colitis Activity Index. NA=not applicable. OTU=operational taxonomic unit. AUC=area under the curve. 
LASSO=least absolute shrinkage and selection operator. *The per-protocol population excludes participants who discontinued the study without additional therapy or colectomy or who had protocol violations. 
†The clinical model was run on the subset of participants with biological data. Clinical model factors with p>0·05 in this smaller cohort were removed from the model. ‡Log relative abundance was calculated by taking 
the log base 10 of the OTU plus half of the minimum value. §Comparison of the clinical plus biological model with clinical model in the subset of patients with biological data.  
Table 3: Multivariable logistic regression models of week 52 corticosteroid-free remission in the per-protocol population
Although in our study severe clinical presentations were 
associated with worse outcomes, some patients with 
severe disease went on to achieve week 52 corticosteroid-
free remission and some with initially mild disease 
required escalation of therapy.
An important finding of our study was the importance 
of early response to mesalazine or corticosteroids and 
achieving clinical remission by week 4 with these 
therapies as predictors of outcome at week 52, and we 
replicated this observation in a large independent cohort. 
A previous retrospective report22 of children with 
ulcerative colitis who underwent a similar treatment 
regimen suggested that PUCAI score at 3 months was 
an important predictor of corticosteroid-free remission 
at 1 year. Early prediction of disease course would be 
preferable and could lead to more timely introduction 
of additional medical therapy beyond mesalazine or 
corticosteroids, especially in those who presented with 
moderate-to-severe disease. Recent guidelines from 
the European Crohn’s and Colitis Organization (ECCO) 
and European Society for Paediatric Gastroenterology 
Hepatology and Nutrition (ESPGHAN) recommend that 
children who present with acute severe colitis who 
respond to intravenous corticosteroids can generally be 
transitioned to thio purines.23 However, our data suggest 
that such a treatment approach might not be necessary 
in all patients if clinical remission is achieved by 4 weeks, 
and that these children should be given an opportunity 
to show their ability to achieve early clinical remission 
and transition to mesalazine before being routinely 
placed on thio purines or anti-TNFα drugs.
We also sought to identify biological predictors of 
disease course. Patients with 25(OH)D concentrations of 
less than 20 ng/mL before treatment were more likely to 
escalate to anti-TNFα therapy than those with con-
centrations of  20 ng/mL or higher before treatment. 
These findings are consistent with a murine study 24 that 
showed the beneficial effects of vitamin D on the function 
of the epithelial barrier of the gut and inflammatory 
immune responses and previous data in adults with 
ulcerative colitis showing worse clinical outcomes were 
associated with low 25(OH)D concentrations.6 Patients 
All patients in clinical model* 
(n=232; 94 [41%] events)
Patients with biological data† (n=118; 43 [39%] events)
Estimate p value Clinical model Clinical plus biological model
Estimate p value Estimate p value
Baseline predictors
Total Mayo score ≥11 4·38 (2·25–8·54) 0·0002 NA ·· NA ··
Rectal biopsy eosinophil peak count >32 per hpf 0·48 (0·25–0·92) 0·027 NA ·· NA ··
Higher 25-hydroxyvitamin D concentration, per increase in category‡ 0·60 (0·37–0·96) 0·034 0·29 (0·11–0·74) 0·010 0·31 (0·14–0·71) 0·0052
Haemoglobin ≥10 g/dL 0·50 (0·26–0·95) 0·033 0·39 (0·20–0·76) 0·0063 0·33 (0·11–0·94) 0·038
Week 4 remission 0·36 (0·19–0·68) 0·0015 0·16 (0·06–0·41) 0·00012 0·21 (0·07–0·58) 0·0029
Transport and antimicrobial gene signature NA ·· NA ·· 0·31 (0·16–0·61) 0·00063
Oscillospira (581079) OTU log relative abundance§ NA ·· NA ·· 0·64 (0·44–0·92) 0·018
Model characteristics
AUC 0·78 (0·72–0·84) ·· 0·80 (0·72–0·88) ·· 0·88 (0·81–0·94) ··
Cross-validated AUC 0·75 (0·68–0·82) ·· 0·75 (0·65–0·84) ·· 0·84 (0·76–0·91) ··
R² 0·32 ·· 0·37 ·· 0·52 ··
Sensitivity 58% (47–68) ·· 63% (49–77) ·· 66% (52–80) ··
Specificity 85% (78–92) ·· 82% (73–91) ·· 83% (74–91) ··
Positive predictive value 73% (61–84) ·· 69% (55–83) ·· 71% (57–85) ··
Negative predictive value.  75% (68–82) ·· 78% (68–87) ·· 79% (70–89) ··
Clinical plus biological model vs clinical model¶
Likelihood ratio test NA NA NA ·· ·· 0·00004
Comparison of AUC NA NA NA ·· ·· 0·016
Hosmer-Lemeshow goodness-of-fit test, median multiple imputation 
p value (proportion of imputations with p >0·05)
·· 0·43 (99%) ·· 0·96 (100%) ·· 0·53 (100%)
Baseline predictors are odds ratios with 95% CIs in parentheses. Missing clinical covariate data were imputed via multiple imputation. Clinical parameters were selected by LASSO. Sensitivity, specificity, 
positive predictive value, and negative predictive value are based on a predicted probability of 0·5. Escalation to anti-TNFα therapy includes one patient starting a calcineurin inhibitor and one who received a 
colectomy without escalation to anti-TNFα therapy. The predicted probability of escalation to anti-TNFα therapy for a patient with mayo score of ≥11, rectal biopsy eosinophil peak count of <32 per hbf, 
serum 25-hydroxyvitamin D concentration of  <20 ng/mL, haemoglobin concentration of <10 g/dL, and no week 4 remission is 0·96 (for equation see appendix). NA=not applicable. hpf=high power field. 
OTU=operational taxonomic unit. AUC=area under the curve. LASSO=least absolute shrinkage and selection operator. TNF=tumor necrosis factor. *Of 237 patients with moderate-to-severe disease who were 
evaluable at week 52, the per-protocol population (n=232) excludes five participants who had protocol violations. †The clinical model was run on the subset of evaluable participants with biological data. 
Clinical model factors with p>0·05 in this smaller cohort were removed from the model. ‡Categories of 25-hydroxyvitamin D are <20 ng/mL; 20 ng/mL to <30 ng/mL; and ≥30 ng/mL. §Log relative abundance 
was calculated by taking the log base 10 of the OTU plus half of the minimum value. ¶Comparison of the clinical plus biological model with clinical model in the subset of patients with biological data.
Table 4: Multivariable logistic regression models of escalation to anti-TNFα therapy by week 52 for patients with moderate-to-severe disease
with rectal eosinophil counts of less than 32 per high-
power field before treatment were more likely to escalate 
to anti-TNFα therapy than those with higher counts, 
which is consistent with data from adult patients with 
ulcerative colitis that showed worse outcomes were 
associated with decreased rectal eosinophils counts.25 
These data suggest that incorporation of baseline 
25(OH)D concentrations and rectal eosinophil counts into 
assessment of the likelihood of escalation to anti-TNFα 
therapy in ulcerative colitis could be helpful, and might 
prioritise clinical trials targeting these pathways.
Shifts in the gut microbial community and host intestinal 
gene expression have been considered in predicting the 
likelihood of response to biological therapies.26–29 Little data 
regarding response to initial therapy with mesalazine and 
corticosteroid exist. We found that decreased expression 
of genes that encode ion channels and transporters 
and increased expression of antimicrobial peptides were 
associated with an increased likelihood of escalation to 
anti-TNFα therapy. The epithelial transport gene signature 
was enriched for guanylin activity, which ameliorates 
murine colitis.30 Although decreased expression of 
α-defensin by Paneth cells has been implicated in the 
pathogenesis of ileal Crohn’s Disease,31 for the first time to 
our knowledge, we linked up-regulated rectal expression of 
α-defensin to an increased refractory course in patients 
with ulcerative colitis who were treatment naive. In this 
context, α-defensins might contribute to colonic injury via 
direct cytotoxic activity and recruitment of inflammatory 
leukocytes.28 We found 28 (with a false discovery rate 
of <0·05) microbial operational taxonomic units were 
linked to clinical outcomes, with the majority from the 
Clostridiales order. Decreased expression of Clostridiales 
at diagnosis was associated with escalation to anti-TNFα 
therapy. This observation is consistent with studies linking 
these taxa to improved function of the colonic barrier and 
anti-inflammatory regulatory T cells.21 
Our study has several limitations and notable strengths. 
Patient enrolment was not population based and so we 
cannot exclude some degree of selection bias. However, the 
29 study centres were representative of paediatric ulcerative 
colitis care in North America. Only 69 (16%) part icipants 
self-identified as non-white, and so our results might not 
be generalisable to a non-white patient population. The 
complexity and expense of completing this study did 
not allow us to develop a similar validation cohort with 
standardised therapy and biological measures. Gene 
expression and microbiome data were available for only a 
subset of participants who strictly followed the treatment 
regimen; therefore, a validation study will be required. 
Furthermore, our results should be interpreted with 
caution because statistical tests were done at a two-sided 
α level of 0·05 with no adjustment. A strength of our study 
that supports the generalisability of our findings is that our 
initial standardised treatment regimen is in harmony with 
recent ECCO and North American Society for Pediatric 
Gastroenterology, Hepatology and Nutrition 
(NASPGHAN) 
guidelines for the treatment of paediatric ulcerative 
colitis23,32 and we prospectively enrolled a large number 
of children with varying disease severity. Our primary 
outcome incidence of corticosteroid-free remis sion on 
mesalazine only is similar to that reported previously from 
an uncontrolled observational registry of children who 
were newly diagnosed with ulcerative colitis,7 and we 
replicated our main clinical model within this group.
Physicians, patients, and families usually seek early 
information that facilitates informed choices when 
balancing the risks and benefits of additional medical 
therapy. Our data will have an immediate clinical effect on 
the treatment of children with ulcerative colitis. By week 4 
after initial therapy with mesalazine or cortico steroid, 
many children declared their treatment response (ie, 
achieved clinical remission). Our validated clinical model 
including baseline severity coupled with week 4 remission 
has good specificity, which will minimise the number of 
false positive results in providing improved confidence 
to guide treatment decisions. Readily available clinical 
indices of severity, rectal eosinophil counts, and 25(OH)D 
con centrations can be used when considering use of anti-
TNFα therapy. Additional studies on rectal gene expression 
and microbial factors in the gut could improve prediction 
of response to initial therapy, identify novel therapeutic 
targets, and help develop personalised approaches to 
improve outcomes in children with ulcerative colitis.
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